BioWorld - Tuesday, February 18, 2025
See today's BioWorld
To read the full story, subscribe or sign in.

Backin’ the RSV: Pfizer expands its programs viral programs with Reviral acquisition

April 7, 2022
By Lee Landenberger
No Comments
Pfizer Inc., with pockets bulging from COVID-19 vaccine money, is taking another step in respiratory syncytial virus (RSV) development with its acquisition of Reviral Ltd.
BioWorld Deals and M&A Acquisition